CLSTN1 and Alzheimer disease: Accordingly, calsyntenin-1 was found to be reduced in AD brains and correlated with increased levels of Aβ, suggesting that an interruption of the calsyntenin-1-associated axonal transport of APP could be a pathogenic mechanism in AD, leading to an increased production of Aβ [57,58].